Methylmalonic Acid (MMA), Quantitative, Urine
Methylmalonyl CoA is the breakdown product of certain amino acids. It is catabolized to succinic acid and cobalamin (Vitamin B12) and hydrolyzed to methylmalonic acid. Methylmalonic acid or MMA is primarily elevated in methylmalonic acidemia, nutritional deficiencies, and vitamin B12 deficiency. Serum MMA is useful in determining early or established vitamin B12 deficiency. B12 levels are decreased either due to lack of dietary intake or a defect in the metabolic pathway of cobalamin. Methylmalonic acidemia can also be caused by an autosomal recessive inborn error of metabolism that is caused by a methylmalonyl CoA mutase enzyme deficiency. Levels in this disorder are markedly increased.
Newborn screening has determined that 1 in every 30,000 has an inborn error of metabolism causing methylmalonic acidemia. Clinical symptoms primarily seen in newborns affected with this disease include failure to thrive, developmental delay, and ketoacidosis. When diagnosed with this disorder, treatment is composed of frequent methylmalonic acid measurements in serum and urine and decreased protein intake in the diet. Excessive protein intake can cause severe life-threatening reactions that are fatal in a majority of the cases. Elevated levels that are not life-threatening include increased MMA levels in vegans and urine (not serum) MMA after meals. Adult patients with megaloblastic anemia secondary to vitamin B12 deficiency have elevated methylmalonic acid (MMA) levels in their serum and urine. Other clinical conditions, including renal insufficiency, hypovolemia, and bacterial overgrowth of the small intestine may be associated with mildly elevated MMA levels.
- Aids in diagnosis of infants or children with symptoms of MMA deficiency
- Aids in evaluation of patients with signs and symptoms of vitamin B12 deficiency
- Diagnosis of methylmalonic acidemia
Increased in:
- Vitamin B-12 deficiency
- Folate deficiency
- Methylmalonyl CoA enzyme deficiency
- Newborn inborn error of metabolism
- Megaloblastic anemia secondary to vitamin B12 deficiency
- Renal insufficiency
- Hypovolemia
- Bacterial overgrowth of the small intestine
| Age Group | µmol/L | mcg/dL |
| Newborn | 0.24–0.39 | 2.8–4.6 |
| 6 wk–6 mo | 0.36–1.51 | 4.2–17.8 |
| 1–10 yr | 0.11–0.17 | 1.3–2.0 |
| 10.5–15 yr | 0.13–0.22 | 1.5–2.6 |
| 15.5–19 yr | 0.12–0.18 | 1.4–2.1 |
| Adults | <0.2 | <2.4 |
| Specimen | g/g creatinine | mmol/mol creatinine |
| Urine | <3.76 | <3.6 |
Urine collected in a sterile urine cup.
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
3-5 days
- Am J Med Genet C Semin Med Genet. 2006. 15;142C(2):104-12. [PMID: 16602092]
- J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):383-9. [PMID: 16763906]
- J Inherit Metab Dis. 2008 Feb;31(1):35-43. [PMID: 17846917]
- J Inherit Metab Dis. 2005;28(3):415-23. [PMID: 15868474]
- Pediatr Nephrol. 2004 Oct;19(10):1071-4. [PMID: 15293040]
- J Inherit Metab Dis. 1995;18(4):430-4. [PMID: 7494401]
- Antony AC. Megaloblastic anemias. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; chap 170 (2007).